Muscle contusions are the most common muscle injuries in sports medicine. Although these injuries are capable of healing, incomplete functional recovery often occurs.
Hypothesis:
Suramin enhances muscle healing by both stimulating muscle regeneration and preventing fibrosis in contused skeletal muscle.
Study Design:
Controlled laboratory study.
Methods:
In vitro: Myoblasts (C2C12 cells) and muscle-derived stem cells (MDSCs) were cultured with suramin, and the potential of suramin to induce their differentiation was evaluated. Furthermore, MDSCs were cocultured with suramin and myostatin (MSTN) to monitor the capability of suramin to neutralize the effect of MSTN. In vivo: Varying concentrations of suramin were injected in the tibialis anterior muscle of mice 2 weeks after muscle contusion injury. Muscle regeneration and scar tissue formation were evaluated by histologic analysis and functional recovery was measured by physiologic testing
Results:
In vitro: Suramin stimulated the differentiation of myoblasts and MDSCs in a dose-dependent manner. Moreover, suramin neutralized the inhibitory effect of MSTN on MDSC differentiation. In vivo: Suramin treatment significantly promoted muscle regeneration, decreased fibrosis formation, reduced myostatin expression in injured muscle, and increased muscle strength after contusion injury.
Conclusion:
Intramuscular injection of suramin after a contusion injury improved overall skeletal muscle healing. Suramin enhanced myoblast and MDSC differentiation and neutralized MSTN's negative effect on myogenic differentiation in vitro, which suggests a possible mechanism for the beneficial effects that this pharmacologic agent exhibits in vivo.
Clinical Relevance:
These findings could contribute to the development of biological treatments to aid in muscle healing after experiencing a muscle injury.
AlameddineHSDehaupasMFardeauM. Regeneration of skeletal muscle fibers from autologous satellite cells multiplied in vitro: An experimental model for testing cultured cell myogenicity. Muscle Nerve. 1989;12:544–555.
2.
BittonRJFiggWDVenzonDJ. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol. 1995;13:2223–2229.
3.
CanaleSTCantlerEDJrSiskTDFreemanBL. A chronicle of injuries of an American intercollegiate football team. Am J Sports Med. 1981;9:384–389.
4.
CarlsonBMFaulknerJA. The regeneration of skeletal muscle fibers following injury: A review. Med Sci Sports Exerc. 1983;15: 187–198.
5.
ChanYSLiYFosterWFuFHHuardJ. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. Am J Sports Med. 2005;33:43–51.
6.
ChanYSLiYFosterW. Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol. 2003;95:771–780.
7.
ChaudryVEisenbergerMASinibaldiVJSheikhHGriffinJWCornblathDR. A prospective study of suramin induced peripheral neuropathy. Brain. 1996;119:2039–2052.
8.
CriscoJJJoklPHeinenGTConnellMDPanjabiMM. A muscle contusion injury model: Biomechanics, physiology, and histology. Am J Sports Med. 1994;22:702–710.
DiazJAFischerDARettigACDavisTJShelbourneKD. Severe quadriceps muscle contusions in athletes: A report of three cases. Am J Sports Med. 2003;31:289–293.
11.
FischmanDA. The synthesis and assembly of myofibrils in embryonic muscle. Curr Top Dev Biol. 1970;5:235–280.
12.
FosterWLiYUsasASomogyiGHuardJ. Gamma interferon as an antifibrosis agent in skeletal muscle. J Orthop Res. 2003;21:798–804.
13.
FukushimaKBadlaniNUsasARianoFFuFHuardJ. The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med. 2001;29:394–402.
14.
GarrettWEJr. Muscle strain injuries: Clinical and basic aspects. Med Sci Sports Exerc. 1990;22:436–443.
15.
GarrettWEJrSafranMRSeaberAVGlissonRRRibbeckBM. Biomechanical comparison of stimulated and nonstimulated skeletal muscle pulled to failure. Am J Sports Med. 1987;15:448–454.
16.
GarrettWEJrSeaberAVBoswickJUrbaniakJRGoldnerJL. Recovery of skeletal muscle after laceration and repair. J Hand Surg [Am]. 1984;9:683–692.
17.
GroundsMD. Towards understanding skeletal muscle regeneration. Pathol Res Pract. 1991;187:1–22.
18.
HawkingF. Suramin: With special reference to onchocerciasis. Adv Pharmacol Chemother. 1978;15:289–322.
19.
HemadyRKSinibaldiVJEisenbergerMA. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Am J Ophthalmol. 1996;121:291–296.
20.
HondaHKimuraHRostamiA. Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle. Immunology. 1990;70:272–277.
21.
HughesC4thHasselmanCTBestTMMartinezSGarrettWEJr. Incomplete, intrasubstance strain injuries of the rectus femoris muscle. Am J Sports Med. 1995;23:500–506.
22.
HurmeTKalimoH. Activation of myogenic precursor cells after muscle injury. Med Sci Sports Exerc. 1992;24:197–205.
23.
HurmeTKalimoHLehtoMJarvinenM. Healing of skeletal muscle injury: An ultrastructural and immunohistochemical study. Med Sci Sports Exerc. 1991;23:801–810.
24.
JacksonDWFeaginJA. Quadriceps contusions in young athletes: Relation of severity of injury to treatment and prognosis. J Bone Joint Surg Am. 1973;55:95–105.
25.
JarvinenMJLehtoMU. The effects of early mobilisation and immobilisation on the healing process following muscle injuries. Sports Med. 1993;15:78–89.
26.
KasemkijwattanaCMenetreyJSomogylG. Development of approaches to improve the healing following muscle contusion. Cell Transplant. 1998;7:585–598.
27.
KobayashiKWeissREVogelzangNJVokesEEJanischLRatainMJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996;78:2411–2420.
28.
LefaucheurJPSebilleA. Muscle regeneration following injury can be modified in vivo by immune neutralization of basic fibroblast growth factor, transforming growth factor beta 1 or insulin-like growth factor I. J Neuroimmunol. 1995;57:85–91.
29.
LevineAMGillPSCohenJ. Suramin antiviral therapy in the acquired immunodeficiency syndrome: Clinical, immunological, and virologic results. Ann Intern Med. 1986;105:32–37.
30.
LiYFosterWDeasyBM. Transforming growth factor-betal induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am J Pathol. 2004;164:1007–1019.
31.
LiYHuardJ. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol. 2002;161:895–907.
32.
MenetreyJKasemkijwattanaCDayCS. Growth factors improve muscle healing in vivo. J Bone Joint Surg Br. 2000;82:131–137.
33.
MenetreyJKasemkijwattanaCFuFHMorelandMSHuardJ. Suturing versus immobilization of a muscle laceration: A morphological and functional study in a mouse model. Am J Sports Med. 1999;27:222–229.
34.
MietzHChevez-BarriosPFeldmanRMLiebermanMW. Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmol. 1998;82:816–820.
35.
QuZBalkirLvan DeutekomJCRobbinsPDPruchnicRHuardJ. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol. 1998;142:1257–1267.
36.
RandoTABlauHM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol. 1994;125:1275–1287.
37.
ReznikMEngelWK. Ultrastructural and histochemical correlations of experimental muscle regeneration. J Neurol Sci. 1970;11:167–185.
38.
RyanJBWheelerJHHopkinsonWJArcieraRAKolakowskiKR. Quadriceps contusions: West Point update. Am J Sports Med. 1991;19:299–304.
39.
SchrellUMGauerSKiesewetterF. Inhibition of proliferation of human cerebral meningioma cells by suramin: Effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg. 1995;82:600–607.
40.
SchultzE. Satellite cell behavior during skeletal muscle growth and regeneration. Med Sci Sports Exerc. 1989;21(5 Suppl):S181–186.
41.
SchultzEJaryszakDLValliereCR. Response of satellite cells to focal skeletal muscle injury. Muscle Nerve. 1985;8:217–222.
42.
SmithAHarbourDLiebmannJ. Acute renal failure in a patient receiving treatment with suramin. Am J Clin Oncol. 1997;20:433–434.
43.
SteinCA. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 1993;53(10 Suppl): 2239–2248.
44.
SullivanKMLorenzHPMeuliMLinRYAdzickNS. A model of scarless human fetal wound repair is deficient in transforming growth factor beta. J Pediatr Surg. 1995;30:198–202.
45.
TaylorDCDaltonJDJrSeaberAVGarrettWEJr. Experimental muscle strain injury: Early functional and structural deficits and the increased risk for reinjury. Am J Sports Med. 1993;21:190–194.
46.
ThomasDWO'NeillIDHardingKGShepherdJP. Cutaneous wound healing: A current perspective. J Oral Maxillofac Surg. 1995;53:442–447.
47.
TisdaleJFFiggWDReedEMcCallNAAlkinsBRHorneMK3rd. Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one. Am J Hematol. 1996;51:152–157.
48.
ZhuJLiYShenW. Relationships between transforming growth factor-betal, myostatin, and decorin: Implications for skeletal muscle fibrosis. J Biol Chem. 2007;282:25852–25863.
49.
ZumkellerWSchofieldPN. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res. 1995;15:343–348.
